Costs of cardiovascular disease prevention care and scenarios for cost saving-Reference-Cited by-同舟云学术

Costs of cardiovascular disease prevention care and scenarios for cost saving

Published:2015-02 Issue:2 Volume:33 Page:376-684
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:

Author:

Hendriks Marleen E.,Bolarinwa Oladimeji A.,Nelissen Heleen E.,Boers Alexander C.,Gomez Gabriela B.,Tan Siok Swan,Redekop William,Adenusi Peju,Lange Joep M.A.,Agbede Kayode,Akande Tanimola M.,Schultsz Constance

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Reference40 articles.

1. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.;Lozano;Lancet,2012

2. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.;Law;BMJ,2009

3. 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.;Lancet,1998

4. Hypertension in sub-Saharan Africa: cross-sectional surveys in four rural and urban communities.;Hendriks;PLoS One,2012

5. Hypertension in sub-Saharan Africa: a systematic review.;Addo;Hypertension,2007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medical costs and incremental medical costs of asthma among workers in the United States;American Journal of Industrial Medicine;2024-07-03

2. The economic burden of treating uncomplicated hypertension in Sub-Saharan Africa: a systematic literature review;BMC Public Health;2022-08-08

3. Cost-effectiveness of a Community-based Hypertension Improvement Project (ComHIP) in Ghana: results from a modelling study;BMJ Open;2021-09

4. Costs of integrating hypertension care into HIV care in rural East African clinics;AIDS;2021-02-03

5. An Ethics-based approach to Global Health Research Part 3: Emphasis on Partnership Funding;Research in Social and Administrative Pharmacy;2020-11